100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R44HL139248
Award Date
9/1/18
Completion Date
5/31/23
Dollars Obligated
$2.1M
Overview
Activity
8
Transactions
8
Subawards
Similar Awards
Federal Agency
National Heart Lung and Blood Institute
Awardee
Invivosciences, Inc. (G5JDXMW3NSW3)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Madison, WI 53719, USA
Update #1
Update #2
HLS-CARDIAC SAFETY AI TRAINED HUMAN HEART AND MICRO HEART MODEL
Posted 8/15/18
5
1
2
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
HLS-CARDIAC SAFETY AI TRAINED HUMAN HEART AND MICRO HEART MODEL - HLS17-12. THE US FDA IS CONSIDERING TO ESTABLISH A NEW CARDIAC SAFETY ASSESSMENT APPROACH DEFINED BY A NEW PARADIGM CALLED, "COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA)". THE CIPA WILL 1) ASSESS DRUG EFFECTS ON EACH CARDIAC ION CHANNEL TYPE INDIVIDUALLY USING A HIGH- THROUGHPUT ASSAY ION CHANNEL ASSAYS, 2) COMPUTE NET EFFECT ON REPOLARIZATION AND RISKS FOR TORSADE POINTES (TDP) USING A MATHEMATICAL MODEL, AND 3) CONFIRM THE COMPUTATIONAL PREDICTION BY MEASURING THE DRUG'S EFFECTS ON ACTION POTENTIALS IN INDUCED PLURIPOTENT STEM CELL (IPSC) DERIVED HUMAN CARDIAC MYOCYTES (CMS). THIS PARADIGM SHIFT, IF SUCCESSFUL, COULD REDUCE THE COST OF CARDIAC SAFETY ANALYSES BY REPLACING OR LOWERING THE REQUIREMENT TO PERFORM AN EXPENSIVE ($2-4 MILLION) THOROUGH QT STUDY DURING CLINICAL TRIALS. PROTECTING CONSUMERS FROM DRUG INDUCED ARRHYTHMIA AND SUDDEN DEATHS IS A PARAMOUNT IMPORTANCE FOR THE REGULATORS AND PHARMACEUTICAL COMPANIES AS WELL AS LOWING THE COST OF DRUG DEVELOPMENT. MANY CARDIAC SAFETY SCIENTISTS, HOWEVER, ARE SKEPTICAL ABOUT CIPA'S APPROACH SINCE CMS DERIVED FROM HUMAN IPSCS EXHIBIT A POOR EXCITATION-CONTRACTION COUPLING DUE TO THEIR IMMATURITY. IN ADDITION, A PROPOSED CIPA MATHEMATICAL MODEL WAS DEVELOPED TO SIMULATE ELECTROPHYSIOLOGY OF HUMAN ADULT CMS, SO THERE IS A MISMATCH BETWEEN EXPERIMENTAL SYSTEM AND COMPUTATIONAL TOOL. TO ADDRESS THESE CONCERNS, WE PROPOSED THREE SPECIFIC AIMS IN TW0 PHASES BY FOLLOWING FAST- TRACK SBIR PROCESSES. PHASE I FEASIBILITY AIM 1 WILL MEASURE DRUG-INDUCED CHANGES IN AP AND CAT USING HUMAN ADULT HEART SLICES ISOLATED FROM HUMAN DONORS. HERE WE WILL CONFIRM OUR SUCCESSFUL HANDLING AND ANALYZING HUMAN ADULT HEART SLICES, WHICH WILL BE BASED ON A RECENTLY PUBLISHED PROTOCOL BY OUR COLLABORATOR, DR. IGOR EFIMOV, AT GEORGE WASHINGTON UNIVERSITY. AFTER THIS VALIDATION, WE WILL MOVE ON TO PERFORM THE FOLLOWING TWO STUDIES: AIM 2. COMPARE DRUG-INDUCED CHANGES IN AP AND CAT IN NUHEARTS GENERATED FROM ADULT CMS AND CARDIAC FIBROBLASTS FROM SAME HUMAN DONOR HEARTS; AIM 3. VALIDATE AND IMPROVE THE COMPUTATIONAL MODELS AND TRAIN AN ARTIFICIAL INTELLIGENCE TO PREDICT CARDIAC SAFETY RISKS OF UNKNOW COMPOUNDS. AFTER OUR SUCCESSFUL COMPLETION PROPOSED PROJECTS, WE CAN ESTABLISH AN UNPRECEDENTED CARDIAC SAFETY ASSESSMENT PLATFORM THAT CAN PREDICT SAFETY ISSUES USING A WELL-TRAINED AI WITHOUT DOING ANY EXPERIMENTS USING HUMAN HEART SLICES THAT ARE RARELY ACCESSIBLE FOR MOST OF THE SAFETY LABORATORIES OR BIOTECH FIRMS.
$0
1/18/24
Not listed
HLS-CARDIAC SAFETY AI TRAINED HUMAN HEART AND MICRO HEART MODEL - HLS17-12. THE US FDA IS CONSIDERING TO ESTABLISH A NEW CARDIAC SAFETY ASSESSMENT APPROACH DEFINED BY A NEW PARADIGM CALLED, "COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA)". THE CIPA WILL 1) ASSESS DRUG EFFECTS ON EACH CARDIAC ION CHANNEL TYPE INDIVIDUALLY USING A HIGH- THROUGHPUT ASSAY ION CHANNEL ASSAYS, 2) COMPUTE NET EFFECT ON REPOLARIZATION AND RISKS FOR TORSADE POINTES (TDP) USING A MATHEMATICAL MODEL, AND 3) CONFIRM THE COMPUTATIONAL PREDICTION BY MEASURING THE DRUG'S EFFECTS ON ACTION POTENTIALS IN INDUCED PLURIPOTENT STEM CELL (IPSC) DERIVED HUMAN CARDIAC MYOCYTES (CMS). THIS PARADIGM SHIFT, IF SUCCESSFUL, COULD REDUCE THE COST OF CARDIAC SAFETY ANALYSES BY REPLACING OR LOWERING THE REQUIREMENT TO PERFORM AN EXPENSIVE ($2-4 MILLION) THOROUGH QT STUDY DURING CLINICAL TRIALS. PROTECTING CONSUMERS FROM DRUG INDUCED ARRHYTHMIA AND SUDDEN DEATHS IS A PARAMOUNT IMPORTANCE FOR THE REGULATORS AND PHARMACEUTICAL COMPANIES AS WELL AS LOWING THE COST OF DRUG DEVELOPMENT. MANY CARDIAC SAFETY SCIENTISTS, HOWEVER, ARE SKEPTICAL ABOUT CIPA'S APPROACH SINCE CMS DERIVED FROM HUMAN IPSCS EXHIBIT A POOR EXCITATION-CONTRACTION COUPLING DUE TO THEIR IMMATURITY. IN ADDITION, A PROPOSED CIPA MATHEMATICAL MODEL WAS DEVELOPED TO SIMULATE ELECTROPHYSIOLOGY OF HUMAN ADULT CMS, SO THERE IS A MISMATCH BETWEEN EXPERIMENTAL SYSTEM AND COMPUTATIONAL TOOL. TO ADDRESS THESE CONCERNS, WE PROPOSED THREE SPECIFIC AIMS IN TW0 PHASES BY FOLLOWING FAST- TRACK SBIR PROCESSES. PHASE I FEASIBILITY AIM 1 WILL MEASURE DRUG-INDUCED CHANGES IN AP AND CAT USING HUMAN ADULT HEART SLICES ISOLATED FROM HUMAN DONORS. HERE WE WILL CONFIRM OUR SUCCESSFUL HANDLING AND ANALYZING HUMAN ADULT HEART SLICES, WHICH WILL BE BASED ON A RECENTLY PUBLISHED PROTOCOL BY OUR COLLABORATOR, DR. IGOR EFIMOV, AT GEORGE WASHINGTON UNIVERSITY. AFTER THIS VALIDATION, WE WILL MOVE ON TO PERFORM THE FOLLOWING TWO STUDIES: AIM 2. COMPARE DRUG-INDUCED CHANGES IN AP AND CAT IN NUHEARTS GENERATED FROM ADULT CMS AND CARDIAC FIBROBLASTS FROM SAME HUMAN DONOR HEARTS; AIM 3. VALIDATE AND IMPROVE THE COMPUTATIONAL MODELS AND TRAIN AN ARTIFICIAL INTELLIGENCE TO PREDICT CARDIAC SAFETY RISKS OF UNKNOW COMPOUNDS. AFTER OUR SUCCESSFUL COMPLETION PROPOSED PROJECTS, WE CAN ESTABLISH AN UNPRECEDENTED CARDIAC SAFETY ASSESSMENT PLATFORM THAT CAN PREDICT SAFETY ISSUES USING A WELL-TRAINED AI WITHOUT DOING ANY EXPERIMENTS USING HUMAN HEART SLICES THAT ARE RARELY ACCESSIBLE FOR MOST OF THE SAFETY LABORATORIES OR BIOTECH FIRMS.
$0
7/29/22
Not listed
HLS-CARDIAC SAFETY AI TRAINED HUMAN HEART AND MICRO HEART MODEL - HLS17-12. THE US FDA IS CONSIDERING TO ESTABLISH A NEW CARDIAC SAFETY ASSESSMENT APPROACH DEFINED BY A NEW PARADIGM CALLED, "COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA)". THE CIPA WILL 1) ASSESS DRUG EFFECTS ON EACH CARDIAC ION CHANNEL TYPE INDIVIDUALLY USING A HIGH- THROUGHPUT ASSAY ION CHANNEL ASSAYS, 2) COMPUTE NET EFFECT ON REPOLARIZATION AND RISKS FOR TORSADE POINTES (TDP) USING A MATHEMATICAL MODEL, AND 3) CONFIRM THE COMPUTATIONAL PREDICTION BY MEASURING THE DRUG'S EFFECTS ON ACTION POTENTIALS IN INDUCED PLURIPOTENT STEM CELL (IPSC) DERIVED HUMAN CARDIAC MYOCYTES (CMS). THIS PARADIGM SHIFT, IF SUCCESSFUL, COULD REDUCE THE COST OF CARDIAC SAFETY ANALYSES BY REPLACING OR LOWERING THE REQUIREMENT TO PERFORM AN EXPENSIVE ($2-4 MILLION) THOROUGH QT STUDY DURING CLINICAL TRIALS. PROTECTING CONSUMERS FROM DRUG INDUCED ARRHYTHMIA AND SUDDEN DEATHS IS A PARAMOUNT IMPORTANCE FOR THE REGULATORS AND PHARMACEUTICAL COMPANIES AS WELL AS LOWING THE COST OF DRUG DEVELOPMENT. MANY CARDIAC SAFETY SCIENTISTS, HOWEVER, ARE SKEPTICAL ABOUT CIPA'S APPROACH SINCE CMS DERIVED FROM HUMAN IPSCS EXHIBIT A POOR EXCITATION-CONTRACTION COUPLING DUE TO THEIR IMMATURITY. IN ADDITION, A PROPOSED CIPA MATHEMATICAL MODEL WAS DEVELOPED TO SIMULATE ELECTROPHYSIOLOGY OF HUMAN ADULT CMS, SO THERE IS A MISMATCH BETWEEN EXPERIMENTAL SYSTEM AND COMPUTATIONAL TOOL. TO ADDRESS THESE CONCERNS, WE PROPOSED THREE SPECIFIC AIMS IN TW0 PHASES BY FOLLOWING FAST- TRACK SBIR PROCESSES. PHASE I FEASIBILITY AIM 1 WILL MEASURE DRUG-INDUCED CHANGES IN AP AND CAT USING HUMAN ADULT HEART SLICES ISOLATED FROM HUMAN DONORS. HERE WE WILL CONFIRM OUR SUCCESSFUL HANDLING AND ANALYZING HUMAN ADULT HEART SLICES, WHICH WILL BE BASED ON A RECENTLY PUBLISHED PROTOCOL BY OUR COLLABORATOR, DR. IGOR EFIMOV, AT GEORGE WASHINGTON UNIVERSITY. AFTER THIS VALIDATION, WE WILL MOVE ON TO PERFORM THE FOLLOWING TWO STUDIES: AIM 2. COMPARE DRUG-INDUCED CHANGES IN AP AND CAT IN NUHEARTS GENERATED FROM ADULT CMS AND CARDIAC FIBROBLASTS FROM SAME HUMAN DONOR HEARTS; AIM 3. VALIDATE AND IMPROVE THE COMPUTATIONAL MODELS AND TRAIN AN ARTIFICIAL INTELLIGENCE TO PREDICT CARDIAC SAFETY RISKS OF UNKNOW COMPOUNDS. AFTER OUR SUCCESSFUL COMPLETION PROPOSED PROJECTS, WE CAN ESTABLISH AN UNPRECEDENTED CARDIAC SAFETY ASSESSMENT PLATFORM THAT CAN PREDICT SAFETY ISSUES USING A WELL-TRAINED AI WITHOUT DOING ANY EXPERIMENTS USING HUMAN HEART SLICES THAT ARE RARELY ACCESSIBLE FOR MOST OF THE SAFETY LABORATORIES OR BIOTECH FIRMS.
$0
7/29/22
Not listed
HLS-CARDIAC SAFETY AI TRAINED HUMAN HEART AND MICRO HEART MODEL
$861.2k
7/22/20
Not listed
HLS-CARDIAC SAFETY AI TRAINED HUMAN HEART AND MICRO HEART MODEL
$0
6/27/19